

15 August 2024

**BEXIMCO PHARMACEUTICALS LIMITED**

**Statement regarding Vice-Chairman, Salman Rahman**

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBBD6TIOQGB56) provides a statement following media reports surrounding the arrest of Non-Executive Vice-Chairman, Mr Salman Rahman.

Mr Rahman was Private Industry and Investment advisor to the Prime Minister of the previous government which, in line with the announcement on 13 August 2024, has now been replaced with an interim government following civil unrest in Bangladesh.

The Company understands that Mr Rahman was arrested by the Dhaka Metropolitan Police on 13 August 2024 and is being remanded in custody for 10 days while an investigation is carried out into alleged offences. The Company is still working to determine the facts of the situation and will provide further information as required.

The previous Prime Minister, as well as a number of other ministers and senior leaders from the previous government, are being investigated in similar cases.

Mr Rahman, in his position as Non-Executive Vice-Chairman, has no role in the day-to-day running of Beximco Pharma.

**For further information please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:**

**Beximco Pharma**

S M Rabbur Reza, Chief Operating Officer  
Tel: +880 2 58611001, Ext.20111

Mohammad Ali Nawaz, Chief Financial Officer  
Tel: +880 2 58611001, Ext.20030

**SPARK Advisory Partners Limited (Nominated Adviser)**

Mark Brady / Andrew Emmott / Adam Dawes  
Tel: +44 (0) 20 3368 3551 / 3555

**SP Angel Corporate Finance LLP (Broker)**

Matthew Johnson  
Tel: +44 (0) 20 3470 0470

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell / Sam Purewal  
Tel: +44 (0) 20 3727 1000

**Notes to Editors**

**About Beximco Pharmaceuticals Limited**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and well-being of people across all the continents by providing

Today, the Company remains committed to health and well-being of people across the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

STRFIFVETEIELIS